Real-world efficacy assessment for sintilimab in recurrent or metastatic cervical cancer.

ABSTRACT:

Background

Programmed death 1 (PD-1) monoclonal antibodies have been reported as a first-line therapeutic option for recurrent cervical cancer, especially for programmed death ligand 1 (PD-L1)-positive tumors. However, real-world data on the use of PD-1 monoclonal antibodies in patients with an undefined PD-L1 status is scarce. This study analyzed the efficacy and safety of sintilimab in patients with recurrent or metastatic cervical cancer.

Methods

Data of patients who received sintilimab for the first time in the First Affiliated Hospital of the Army Medical University from November 2019 to July 2022 were collected. The efficacy and safety of sintilimab were evaluated according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and Common Terminology

SUBMITTER: Zhou D 

PROVIDER: S-EPMC12721100 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature